Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Omicron (B.1.1.529) Variant: Development, Dissemination, and Dominance Publisher Pubmed



Rahmani S1, 2 ; Rezaei N2, 3, 4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  2. 2. Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran
  3. 3. Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Source: Journal of Medical Virology Published:2022


Abstract

[No abstract available]
Related Docs
1. Sars-Cov-2 Omicron (B.1.1.529) Variant: A Challenge With Covid-19, Diagnostics (2023)
2. Sars-Cov-2 Omicron (B.1.1.529) Variant: No Time to Wait!, Acta Biomedica (2022)
3. Sars-Cov-2 Omicron Variant: Why Global Communities Should Take It Seriously?, Immunity# Inflammation and Disease (2022)
4. Molecular Variants of Sars-Cov-2: Antigenic Properties and Current Vaccine Efficacy, Medical Microbiology and Immunology (2022)
Experts (# of related papers)
Nima Rezaei (2)
Seyed Rohollah Miri (1)